Denosumab: RANKL inhibition in the management of bone loss

Drugs of Today

Volumn 44, Issue 1, 2008, Pages 7-21

  Hamdy, Neveen A T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLONY STIMULATING FACTOR 1; CREATININE; CROSS REACTING ANTIBODY; DENOSUMAB; DEXAMETHASONE; DRUG ANTIBODY; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT OSTEOPROTEGERIN CONJUGATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANTIBODY PRODUCTION; BLOOD CLOTTING; BONE ATROPHY; BONE CANCER; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE EROSION; BONE MASS; BONE METASTASIS; BONE NECROSIS; BONE REMODELING; BONE STRENGTH; BREAST CANCER; CALCIFICATION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE URINE LEVEL; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN DEFICIENCY; FRACTURE; GENETIC MODEL; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; IMMUNOLOGICAL PARAMETERS; INFECTION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE REMODELING; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; NEOPLASMS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 40849111556     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.1.1178467     Document Type: Review

References (63)

1. Manolagas, S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21(2): 115-37.
2. Martin, T.J., Seeman, E. New mechanisms and targets in the treatment of bone fragility. Clin Sci 2007, 112(2): 77-91.
3. Baron, R. Arming the osteoclasts. Nat Med 2004, 10(5): 458-60.
4. Walsh, M.C., Kim, N., Kadono, Y. et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24: 33-63
5. Tanaka, S., Takahashi, N., Udagawa, N. et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993, 91(1): 257-63.
6. Boyle, W.J., Simonet, W.S., Lacey, D.L. Osteoclast differentiation and activation. Nature 2003, 423(6937): 337-42.
7. Duong, L.T., Rodan, G.A. Regulation of osteoclast formation and function. Rev Endocr Metab Disord 2001, 2(1): 95-104.
8. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T., Martin, T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20(3): 345-57.
9. Teitelbaum, S.L. Bone resorption by osteoclasts. Science 2000, 289(5484): 1504-8.
10. Li, J., Sarosi, I., Yan, X.Q. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000 Feb 15, 97(4): 1566-71.
11. Teitelbaum, S.L. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther 2006, 8(1): 201.
12. Boyce, B.F., Schwarz, E.M., Xing, L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol 2006, 18(4): 427-32.
13. Miranda-Carus, M.E., Benito-Miguel, M., Balsa, A. et al. Peripheral blood Tlymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006, 54(4): 1151-64.
14. Franchimont, N., Reenaers, C., Lambert, C. et al. Increased expression of receptor activator of NF-kappa B ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004, 138(3): 491-8.
15. Moschen, A.R., Kaser, A., Enrich, B. et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005, 54(4): 479-87.
16. Heider, U., Zavriski, I., Jakob, C. et al. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. J Cancer Res Clin Oncol 2004, 130(8): 469-74.
17. Sezer, O., Heider, U., Zavriski, I., Kuhne, C.A., Hofbauer, L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003, 101(6): 2094-8.
18. Dougau, W., Tometsko, M., Armstrong, A. et al. RANK ligand directly induces osteoclastogenic, angiogenic, chemoattractive and invasive factors on RANK-expressing human cancer cells MDA-MB-231 and PC3. Cancer Treat Rev 2005, 31(Suppl. 1): S24.
19. Mundy, G.R. The bone microenvironment and metastasis. Cancer Treat Rev 2005, 31(Suppl. 1): S11.
20. Simonet, W.S., Lacey, D.L., Dunstan, C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89(2): 309-19.
21. Emery, J.G., McDonnell, P., Burke, M.B. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273(23): 14363-7.
22. Raisz, L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005, 115(12): 3318-25.
23. Riggs, B.L., Sundeep, K., Melton, L.J. III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23(3): 279-302.
24. Rodan, G.A., Martin, T.J. Therapeutic approaches to bone diseases. Science 2000, 289(5484): 1508-14.
25. Bucay, N., Sarosi, I., Dunstan, C.R. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12(9): 1260-8.
26. Kong, Y.Y., Yoshida, H., Sarosi, I. et al. OPGL is a key regulator of osteoclastogenesis, lym phocyte development and lymph-node organogenesis. Nature 1999, 397(6717): 315-23.
27. Pacifici, R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996, 11(8): 1043-51.
28. Weitzmann, M.N., Pacifici, R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006, 116(5): 1186-94.
29. Hofbauer, L.C., Khosla, S., Dunstan, C.R., Lacey, D.L., Spelsberg, T.C., Riggs, B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140(9): 4367-70.
30. Shevde, N.K., Bendixen, A., Dienger, K.M., Pike. J.W: Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000, 977: 829-34.
31. Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W.J., Lacey, D.L., Riggs, B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003,111(8): 1221-30.
32. Hofbauer, L.C., Gori, F., Riggs, B.L. et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis Endocrinology 1999, 140: 4382-9.
33. Sivagurunathan, S., Muir, M.M., Brennan, T.C., Seale, J.P., Mason, R.S. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 2005, 20(3): 390-8.
34. Sasaki, N., Kusano, E., Ando, Y. et al. Glucocorticoid decreases circulating osteoprotegerin (OPG). Nephrol Dial Transplant 2001,16(3): 479-82.
35. Brown, J.E., Thompson, C.S., Ellis, S.P., Gutcher, S.A., Purohit, O.P., Coleman, R.E. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003, 89(11): 2031-7.
36. Heider, U., Langelotz, C., Jakob, C. et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003, (4): 1436-40.
37. Hofbauer, L.C., Schoppet, M. Clinical implications of the osteoprotegerin/ RANKL/ RANK system for bone and vascular diseases. JAMA 2004, 292(4): 490-5.
38. Ritchlin, C.T., Haas-Smith, S.A., Li, P., Hicks, D.G., Schwarz, E.M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111(6): 821-31.
39. Abu-Amer, Y., Darwech, I., Clohisy, J.C. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther 2007, 9(Suppl. 1): S6.
40. Min, H., Morony, S., Sarosi, I. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192(4): 463-74.
41. Hofbauer, L.C., Brueck, C.C., Shanahan, C.M. Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos Int 2007, 18(3): 251-9.
42. Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 4:496-551.
43. Hamdy, N.A. Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep 2006, 8(1): 50-4.
44. Hamdy, N.A. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr Opin Investig Drugs 2007, 8(4): 299-303.
45. Schwarz, E.M., Ritchlin, C.T. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007, 9(Suppl. 1): S7.
46. Caparelli, C., Morony, S., Warmington, K. et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res. 2003, 18(5): 852-8.
47. Ross, A.B., Bateman, T.A., Kostenuik, P.J. et al. The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 2001, 12(7): 583-8.
48. Ulrich-Vinther, M., Andreassen, T.T. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int 2005 Apr;76(4):280-6.
49. Kostenuik, P.J., Caparelli, C., Morony, S. et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinol 2001, 142(10): 4295-304.
50. Ominsky, M.S., Kostenuik, R.J., Cranmer, P., Smith, S.Y., Atkinson, J.E. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 2007, 18(8): 1073-82.
51. Kostenuik, P.J., Paul, C., Smith, S., Asuncion, F., Atkinson, J. The RANKL antagonist OPG-Fc causes significant increases in cortical bone mineral area, content and density in adult cynomolgus monkeys. J Bone Miner Res 2004, 19(Suppl. 1): S19.
52. Morony, S., Lu, J., Caparelli, C., Dunstan, C.R., Lacey, D.L., Kostenuik, P.J. Osteoprotegerin (OPG) prevents bone loss in a rat model of glucocorticoid-induced osteopopenia. J Bone Miner Res 2001, 16(Suppl. 1): S148.
53. Stolina, M., Adamu, S., Ominsky, M. et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005, 20(10): 1756-65.
54. Morony, S., Caparelli, C., Sarosi, I., Lacey, D.L., Dunstan, C.R., Kostenuik, P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61(11): 4432-6.
55. Croucher, P., Holen, I., Eaton, C. Nonosseous effects of osteoprotegerin. Cancer Treat Rev 2005, 31(Suppl. 1): S14.
56. Bekker, P.J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P.T., Dunstan, C.R. The ef feet of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16(2): 348-60.
57. Body, J.J., Greipp, P., Coleman, R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97(Suppl. 3): 887-92.
58. Bekker, P.J., Holloway, D., Rasmussen, A.S. et al. A single-dose placebo-controlled study of AMG 162, fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19(7): 1059-66.
59. Peterson, M.C., Ni, L., Salfi, M. et al. Pharmacokinetics (PK), pharmacodynamics (PD) and safety of AMG 162, a fully human monoclonal antibody to RANKL, following a single subcutaneous dose to healthy men aged 50 years and older. Bone 2005, 36(Suppl. 2): S399.
60. Body, J.J., Facon, T., Coleman, R.E. et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12(4): 1221-8.
61. McClung, M.R., Lewiecki, E.M., Cohen, S.B. et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006, 354: 821-31.
62. Delmas, P.D. Bone structural geometry: the impact of RANKL inhibition. Osteopor Int 2007, 18(Suppl. 1): S189.
63. Whyte, M.P. The long and the short of bone therapy. N Engl J Med 2006, 354(8): 860-3.